1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, and.
2 Unit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Am J Respir Cell Mol Biol. 2018 Sep;59(3):295-305. doi: 10.1165/rcmb.2017-0419OC.
Progressive fibrosis is a complication of many chronic diseases, and collectively, organ fibrosis is the leading cause of death in the United States. Fibrosis is characterized by accumulation of activated fibroblasts and excessive deposition of extracellular matrix proteins, especially type I collagen. Extensive research has supported a role for matrix signaling in propagating fibrosis, but type I collagen itself is often considered an end product of fibrosis rather than an important regulator of continued collagen deposition. Type I collagen can activate several cell surface receptors, including αβ integrin and discoidin domain receptor 2 (DDR2). We have previously shown that mice deficient in type I collagen have reduced activation of DDR2 and reduced accumulation of activated myofibroblasts. In the present study, we found that DDR2-null mice are protected from fibrosis. Surprisingly, DDR2-null fibroblasts have a normal and possibly exaggerated activation response to transforming growth factor-β and do not have diminished proliferation compared with wild-type fibroblasts. DDR2-null fibroblasts are significantly more prone to apoptosis, in vitro and in vivo, than wild-type fibroblasts, supporting a paradigm in which fibroblast resistance to apoptosis is critical for progression of fibrosis. We have identified a novel molecular mechanism by which DDR2 can promote the activation of a PDK1 (3-phosphoinositide dependent protein kinase-1)/Akt survival pathway, and we have found that inhibition of PDK1 can augment fibroblast apoptosis. Furthermore, our studies demonstrate that DDR2 expression is heavily skewed to mesenchymal cells compared with epithelial cells and that idiopathic pulmonary fibrosis cells and tissue demonstrate increased activation of DDR2 and PDK1. Collectively, these findings identify a promising target for fibrosis therapy.
进行性纤维化是许多慢性疾病的并发症,而器官纤维化是美国主要的死亡原因。纤维化的特征是激活的成纤维细胞积累和细胞外基质蛋白(尤其是 I 型胶原)的过度沉积。大量研究支持基质信号在传播纤维化中的作用,但 I 型胶原本身通常被认为是纤维化的终产物,而不是持续胶原沉积的重要调节剂。I 型胶原可以激活几种细胞表面受体,包括αβ整联蛋白和盘状结构域受体 2(DDR2)。我们之前的研究表明,缺乏 I 型胶原的小鼠中 DDR2 的激活减少,激活的肌成纤维细胞的积累减少。在本研究中,我们发现 DDR2 缺失的小鼠免受纤维化的影响。令人惊讶的是,DDR2 缺失的成纤维细胞对转化生长因子-β的激活反应正常,甚至可能增强,与野生型成纤维细胞相比,增殖能力没有降低。与野生型成纤维细胞相比,DDR2 缺失的成纤维细胞在体外和体内更容易发生凋亡,这支持了成纤维细胞对凋亡的抵抗对于纤维化进展至关重要的观点。我们已经确定了一种新的分子机制,即 DDR2 可以促进 PDK1(3-磷酸肌醇依赖性蛋白激酶-1)/Akt 存活途径的激活,并且我们发现抑制 PDK1 可以增强成纤维细胞的凋亡。此外,我们的研究表明,与上皮细胞相比,DDR2 在间充质细胞中的表达严重偏向,特发性肺纤维化细胞和组织显示 DDR2 和 PDK1 的激活增加。总之,这些发现为纤维化治疗确定了一个有前途的靶点。